Literature DB >> 16279788

Urotensin-II receptor ligands. From agonist to antagonist activity.

Paolo Grieco1, Alfonso Carotenuto, Pietro Campiglia, Luciana Marinelli, Teresa Lama, Riccardo Patacchini, Paolo Santicioli, Carlo A Maggi, Paolo Rovero, Ettore Novellino.   

Abstract

Urotensin II (U-II) is a disulfide bridged peptide hormone recently identified as the ligand of a G-protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-cyclo[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. We have recently identified both a superagonist of hU-II termed P5U and the compound termed urantide, which is the most potent UT receptor peptide antagonist described to date. Our previous conformational studies showed that hU-II and its analogues with agonist activity adopt a well-defined type II' beta-hairpin structure in anisotropic SDS membrane-like environment. This structural arrangement allows tight contact among the Trp7, Lys8, and Tyr9 side chains, which is fundamental to obtain full agonist activity. Here, we report an extensive SAR study on new analogues with agonist/antagonist activity on UT receptor. We investigated their biological activity and performed a conformational analysis by spectroscopic and computational methods. Our goal is to obtain a structure-based model able to explain the agonist/antagonist functional switching of these ligands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279788     DOI: 10.1021/jm058043j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

Authors:  Brian J Holleran; Marie-Eve Beaulieu; Christophe D Proulx; Pierre Lavigne; Emanuel Escher; Richard Leduc
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

2.  Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations.

Authors:  Soo-Kyung Kim; Youyong Li; Changmoon Park; Ravinder Abrol; William A Goddard
Journal:  ChemMedChem       Date:  2010-09-03       Impact factor: 3.466

Review 3.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

4.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

5.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.

Authors:  Francesco Merlino; Salvatore Di Maro; Ali Munaim Yousif; Michele Caraglia; Paolo Grieco
Journal:  J Amino Acids       Date:  2013-02-25

6.  Molecular subsets in the gene expression signatures of scleroderma skin.

Authors:  Ausra Milano; Sarah A Pendergrass; Jennifer L Sargent; Lacy K George; Timothy H McCalmont; M Kari Connolly; Michael L Whitfield
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.